Cellbox Solutions closes €3.5 million growth round
German biotech logistics startup Cellbox Solutions has raised €3.5 million to accelerate the global rollout of its specialized transport technology for living cells. The fresh capital will help the company scale production, deepen international partnerships and expand its footprint in the fast‑growing market for advanced cell and gene therapies.
Enabling safe, mobile transport of living cells
Cellbox Solutions develops portable, temperature‑ and CO₂‑controlled systems that allow researchers, biopharma companies and clinical centers to ship sensitive biological material while maintaining its viability. Unlike traditional cold‑chain containers, the company’s technology is designed to keep cells in a stable, incubator‑like environment during transit.
This approach aims to reduce cell damage, improve reproducibility of experiments and support the emerging ecosystem around personalized medicine, where living cell therapies often need to be moved quickly and safely between manufacturing sites and hospitals.
Fuel for international expansion
The €3.5 million funding will be directed toward ramping up manufacturing capacity, investing in product development and strengthening sales and service networks in key markets across Europe, North America and Asia. By building out a global logistics infrastructure, Cellbox Solutions seeks to position itself as a critical enabler for biotech, pharmaceutical and clinical research organizations.
Riding the wave of cell and gene therapy growth
Demand for robust, compliant transport solutions is rising as more cell and gene therapy candidates enter clinical trials and commercial use. Regulators and industry alike are placing heightened emphasis on quality control, cold‑chain integrity and end‑to‑end traceability, creating a favorable environment for specialized logistics technologies.
With this latest funding, Cellbox Solutions aims to broaden its product portfolio, integrate smarter monitoring and tracking technologies, and work closely with partners to standardize best practices for moving living biological materials around the world. The company’s strategy underscores how advanced transport technology is becoming a foundational layer of the modern life‑science value chain.